vs
Side-by-side financial comparison of EDGEWELL PERSONAL CARE Co (EPC) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $422.8M, roughly 1.5× EDGEWELL PERSONAL CARE Co). Royalty Pharma plc runs the higher net margin — 34.4% vs -15.5%, a 50.0% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs -11.6%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -16.0%).
The Edgewell Personal Care Company is an American multinational consumer products company headquartered in Shelton, Connecticut. It was formed in 2015 following the corporate spin-off from Energizer Holdings, Inc..
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
EPC vs RPRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $422.8M | $622.0M |
| Net Profit | $-65.7M | $214.2M |
| Gross Margin | 38.1% | — |
| Operating Margin | -4.5% | 62.4% |
| Net Margin | -15.5% | 34.4% |
| Revenue YoY | -11.6% | 4.8% |
| Net Profit YoY | -3028.6% | 2.9% |
| EPS (diluted) | $-1.41 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $422.8M | $622.0M | ||
| Q3 25 | $600.5M | $609.3M | ||
| Q2 25 | $627.2M | $578.7M | ||
| Q1 25 | $580.7M | $568.2M | ||
| Q4 24 | $415.1M | $593.6M | ||
| Q3 24 | $517.6M | $564.7M | ||
| Q2 24 | $647.8M | $537.3M | ||
| Q1 24 | $599.4M | $568.0M |
| Q4 25 | $-65.7M | $214.2M | ||
| Q3 25 | $-30.6M | $288.2M | ||
| Q2 25 | $29.1M | $30.2M | ||
| Q1 25 | $29.0M | $238.3M | ||
| Q4 24 | $-2.1M | $208.2M | ||
| Q3 24 | $8.8M | $544.0M | ||
| Q2 24 | $49.0M | $102.0M | ||
| Q1 24 | $36.0M | $4.8M |
| Q4 25 | 38.1% | — | ||
| Q3 25 | 37.9% | — | ||
| Q2 25 | 42.8% | — | ||
| Q1 25 | 44.1% | — | ||
| Q4 24 | 41.6% | — | ||
| Q3 24 | 41.1% | — | ||
| Q2 24 | 44.3% | — | ||
| Q1 24 | 43.1% | — |
| Q4 25 | -4.5% | 62.4% | ||
| Q3 25 | -4.2% | 70.1% | ||
| Q2 25 | 8.6% | 36.3% | ||
| Q1 25 | 10.1% | 94.0% | ||
| Q4 24 | 2.2% | 60.9% | ||
| Q3 24 | 3.9% | — | ||
| Q2 24 | 12.8% | 50.2% | ||
| Q1 24 | 11.7% | -13.0% |
| Q4 25 | -15.5% | 34.4% | ||
| Q3 25 | -5.1% | 47.3% | ||
| Q2 25 | 4.6% | 5.2% | ||
| Q1 25 | 5.0% | 41.9% | ||
| Q4 24 | -0.5% | 35.1% | ||
| Q3 24 | 1.7% | 96.3% | ||
| Q2 24 | 7.6% | 19.0% | ||
| Q1 24 | 6.0% | 0.8% |
| Q4 25 | $-1.41 | $0.49 | ||
| Q3 25 | $-0.65 | $0.67 | ||
| Q2 25 | $0.62 | $0.07 | ||
| Q1 25 | $0.60 | $0.55 | ||
| Q4 24 | $-0.04 | $0.46 | ||
| Q3 24 | $0.18 | $1.21 | ||
| Q2 24 | $0.98 | $0.23 | ||
| Q1 24 | $0.72 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $618.7M |
| Total DebtLower is stronger | $1.5B | $9.0B |
| Stockholders' EquityBook value | $1.5B | $9.7B |
| Total Assets | $3.8B | $19.6B |
| Debt / EquityLower = less leverage | 1.03× | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $618.7M | ||
| Q3 25 | — | $938.9M | ||
| Q2 25 | — | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $929.0M | ||
| Q3 24 | $209.1M | $950.1M | ||
| Q2 24 | — | $1.8B | ||
| Q1 24 | — | $843.0M |
| Q4 25 | $1.5B | $9.0B | ||
| Q3 25 | $1.4B | $8.9B | ||
| Q2 25 | $1.4B | $8.0B | ||
| Q1 25 | $1.4B | $7.6B | ||
| Q4 24 | $1.4B | $7.6B | ||
| Q3 24 | $1.3B | $7.6B | ||
| Q2 24 | $1.3B | $7.6B | ||
| Q1 24 | $1.4B | $6.1B |
| Q4 25 | $1.5B | $9.7B | ||
| Q3 25 | $1.6B | $9.6B | ||
| Q2 25 | $1.6B | $9.5B | ||
| Q1 25 | $1.5B | $9.8B | ||
| Q4 24 | $1.5B | $10.3B | ||
| Q3 24 | $1.6B | $10.3B | ||
| Q2 24 | $1.6B | $9.8B | ||
| Q1 24 | $1.6B | $9.9B |
| Q4 25 | $3.8B | $19.6B | ||
| Q3 25 | $3.8B | $19.3B | ||
| Q2 25 | $3.8B | $18.3B | ||
| Q1 25 | $3.8B | $17.6B | ||
| Q4 24 | $3.7B | $18.2B | ||
| Q3 24 | $3.7B | $18.0B | ||
| Q2 24 | $3.7B | $17.7B | ||
| Q1 24 | $3.8B | $16.1B |
| Q4 25 | 1.03× | 0.92× | ||
| Q3 25 | 0.89× | 0.93× | ||
| Q2 25 | 0.88× | 0.84× | ||
| Q1 25 | 0.95× | 0.78× | ||
| Q4 24 | 0.97× | 0.74× | ||
| Q3 24 | 0.81× | 0.74× | ||
| Q2 24 | 0.82× | 0.78× | ||
| Q1 24 | 0.88× | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-125.9M | $827.1M |
| Free Cash FlowOCF − Capex | $-137.5M | — |
| FCF MarginFCF / Revenue | -32.5% | — |
| Capex IntensityCapex / Revenue | 2.7% | — |
| Cash ConversionOCF / Net Profit | — | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | $36.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-125.9M | $827.1M | ||
| Q3 25 | $74.1M | $702.6M | ||
| Q2 25 | $114.8M | $364.0M | ||
| Q1 25 | $45.1M | $596.1M | ||
| Q4 24 | $-115.6M | $742.5M | ||
| Q3 24 | $-388.3M | $703.6M | ||
| Q2 24 | $101.2M | $658.2M | ||
| Q1 24 | $129.0M | $664.6M |
| Q4 25 | $-137.5M | — | ||
| Q3 25 | $46.5M | — | ||
| Q2 25 | $99.3M | — | ||
| Q1 25 | $28.0M | — | ||
| Q4 24 | $-132.4M | — | ||
| Q3 24 | $-414.2M | — | ||
| Q2 24 | $88.6M | — | ||
| Q1 24 | $117.5M | — |
| Q4 25 | -32.5% | — | ||
| Q3 25 | 7.7% | — | ||
| Q2 25 | 15.8% | — | ||
| Q1 25 | 4.8% | — | ||
| Q4 24 | -31.9% | — | ||
| Q3 24 | -80.0% | — | ||
| Q2 24 | 13.7% | — | ||
| Q1 24 | 19.6% | — |
| Q4 25 | 2.7% | — | ||
| Q3 25 | 4.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | 2.9% | — | ||
| Q4 24 | 4.0% | — | ||
| Q3 24 | 5.0% | — | ||
| Q2 24 | 1.9% | — | ||
| Q1 24 | 1.9% | — |
| Q4 25 | — | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | 3.95× | 12.06× | ||
| Q1 25 | 1.56× | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | -44.13× | 1.29× | ||
| Q2 24 | 2.07× | 6.45× | ||
| Q1 24 | 3.58× | 139.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EPC
| Other | $242.0M | 57% |
| Sunand Skin Care Segment | $131.5M | 31% |
| Shavinggelsandcreams | $32.3M | 8% |
| Wipes And Other Skin Care Products | $17.0M | 4% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
